Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | Management of BPDCN: the relevance of chemotherapy in the era of targeted agents

Naveen Pemmaraju, MD, University of Texas MD Anderson Cancer Center, Houston, TX, comments on the role of chemotherapy in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), highlighting data from a Phase II study comparing the outcomes of patients with BPDCN who received frontline hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate/ARA-C (HCVAD)-based vs non-HCVAD based treatment regimens (NCT04216524). The study highlighted the important role of HCVAD-based chemotherapy in these patients, even in the context of targeted therapies including CD123-targeting agents. Dr Pemmaraju also comments on the need for combination approaches with chemotherapy, targeted therapies and central nervous system (CNS)-directed therapies and argues that such strategies could lead to the long-term eradication of BPDCN. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Disclosures

Naveen Pemmaraju, MD, is a member of the ASH Communications Committee and the ASCO Leukemia Advisory panel; has participated in consultancy work for Pacylex Pharmaceuticals, ImmuniGen, Bristol Myers Squibb, Blueprint Medicines, Clearview Healthcare Partners, Astellas Pharma US Inc., Triptych Health Partners and CTI Biopharma; has received grants from Affymetrix and SagerStrong Foundation; has received honoraria from Incyte, Novartis, LFB Biotechnologies, Stemline Therapeutics, Celgene, AbbVie, MustangBio, Roche Diagnostics, Blueprint Medicines, DAVA Oncology, Springer Science + Business Media LLC, Aptitude Health, NeoPharm Israel and CareDx, Inc., has received research support from Novartis, Stemline Therapeutics, Samus Therapeutics, AbbVie, Cellectis, Affymetrix, Daiichi Sankyo and Plexxikon; and has received travel reimbursement from Stemline Therapeutics, Celgene, MustangBio, DAVA Oncology and AbbVie.